Pitch dark? In funding bid, be open about challenges they'll find anyway: panel
16 September 2016
Tweaks were made this year to the format of Biopharm America, which featured shorter, snappier sessions intended to stimulate exactly the kind of early partnering talks that the event is designed to foster.
U.K. biopharma sector delivers wish list for Brexit negotiations
16 September 2016
After a summer of concerted effort to scope out and reach a unified view, the life sciences sector had its first meeting with the government's new Department for Exiting the EU, to put forward the industry's wish list and requirements once negotiations on U.K. withdrawal from the EU get underway.
16 September 2016
Biotechnology companies received the second largest amount of corporate venture dollars in the second quarter, attracting $407 million in 25 deals, representing 33 percent of corporate venture dollars invested and 12.6 percent of deals. As a share of overall venture dollars invested in biotechnology companies, corporate venture groups accounted for 24.2 percent of total dollars invested, which was substantially over-weighted in the sector.
New drug combo targets an aggressive blood cancer at lower cost
15 September 2016
Patients with chronic myeloid leukemia (CML) face not only a life-threatening cancer but also the high cost of the current therapy. A team at the University of Texas has now shown a drug combo that might stop the cancer--while offering the drug at a more reasonable price tag.
A Global Fight Against Antimicrobial Resistance
14 September 2016
The European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) met on Sept. 1–2, 2016 to discuss a worldwide regulatory response to the development of new antibiotics to fight antimicrobial resistance. The agencies agreed at the meeting, which was hosted by EMA, that regulatory activities were only one facet of the response needed to fight antimicrobial resistance worldwide.
New medicines in development for autoimmune diseases offer patients hope for brighter futures
14 September 2016
Currently, more than 23.5 million Americans are affected by one of the more than 80 autoimmune diseases identified to date. These diseases range in severity, with their own characteristics and their own struggles. Because of this, the need for innovative treatments and cures has never been greater. But today, patients with an autoimmune disease can have more hope than ever before with the tremendous progress that science offers patients and their families.
Keep the EMA in London, Japan says, warning that pharma HQs could leave post-Brexit
14 September 2016
Japan is warning that investments in the U.K. could be at risk with Brexit, if the negotiations drag on and are kept under wraps. And that includes pharma companies exiting the country.
13 September 2016
Russia has risen from 54th to 51st place in the World Bank's 2016 Ease of Doing Business ranking and we entrepreneurs in the pharmaceutical industry feel that change is happening for the better. Supporting the development of local pharmaceutical production of medicines has been declared a priority by the state, and as a result, the share of drugs produced by Russian companies on the market is increasing. The Russian pharmaceutical industry as a whole is maturing — it has begun to attract people and investment from other sectors and the main investment activity is shifting from producing finished dosage forms to research and development. Additionally, Russian pharmaceutical firms are pursuing access to foreign markets.
Innovation vs. Capacity: How CMOs Compete
13 September 2016
While industry participants and observers talk about the “CMO industry,” they know that it is not an undifferentiated mass of manufacturers. The contract and manufacturing organization (CMO) industry can be segmented along obvious lines such as API versus drug product manufacturers, biologics versus small molecule, dose form(s) manufactured, and geographic focus. But none of these designations reflect the strategies that each CMO is pursuing, and without that basic understanding, one cannot fully understand the prospects for the industry.
CRISPR cuts out $90M IPO bid as another gene editing biotech goes public
13 September 2016
Finally following in the wake of Editas and Intellia, CRISPR Therapeutics has decided to buck the tumultuous 2016 IPO trend by going public with its highly sought-after tech.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024